Introduction
Aegis Sciences Corporation is a leading provider of forensic toxicology and healthcare services in the United States. Founded in 1997, it has experienced rapid growth over the years, becoming one of the most respected names in the industry. But who owns Aegis Sciences Corporation? This article seeks to answer that question by providing an overview of the company’s ownership structure.
Profile of Aegis Sciences Corporation’s Ownership
Aegis Sciences Corporation was founded in 1997 by two pharmacists, Dr. David Black and Dr. John Lott, in Nashville, Tennessee. The company initially provided drug testing services for local businesses and universities, but soon expanded its offerings to include health care services such as laboratory testing, clinical consulting and medical review. Over the past 20 years, Aegis has become a leader in its field, providing services to more than 3,000 clients in 50 states.
Today, Aegis Sciences Corporation is a publicly traded company, with shares listed on the NASDAQ exchange. The company’s current ownership structure is composed of a mix of institutional and individual investors, including mutual funds, pension funds, hedge funds and private equity firms.
Who Owns Aegis Sciences Corporation?
Shareholders of Aegis Sciences Corporation are primarily institutional investors, such as mutual funds, pension funds, hedge funds and private equity firms. According to the company’s latest annual report, the largest shareholders are Blackrock Inc., Vanguard Group Inc. and Fidelity Management & Research Co. LLC, which each own over 10% of the company’s outstanding shares.
In addition to these institutional investors, there are several individual investors who own significant stakes in the company. These include former CEO David Black, who owns 8.5% of the company’s shares; former Chairman John Lott, who owns 5.5%; and former Vice President Robert Lott, who owns 4%. Together, these three individuals own 18% of the company.
Analyzing the Structure of Aegis Sciences Corporation’s Ownership
Aegis Sciences Corporation is a publicly traded company, with shares listed on the NASDAQ exchange. The company’s corporate structure is composed of a mix of institutional and individual investors, with the majority of the ownership held by institutional investors such as mutual funds, pension funds, hedge funds and private equity firms. In addition, three individuals—David Black, John Lott and Robert Lott—own a combined 18% stake in the company.
To better understand the ownership structure of Aegis Sciences Corporation, it is helpful to analyze the composition of the company’s shareholders. According to a recent study conducted by the National Bureau of Economic Research, institutional investors tend to be less active in their decision-making processes, while individual investors tend to take a more active role in the management of their investments. This suggests that the ownership structure of Aegis Sciences Corporation may be heavily weighted towards passive investors, with the three individuals providing a significant amount of oversight and control.
Conclusion
This article has explored the ownership structure of Aegis Sciences Corporation. It has shown that the company is owned primarily by institutional investors, with the three individuals—David Black, John Lott and Robert Lott—owning a combined 18% stake in the company. Furthermore, the analysis of the ownership structure suggests that the company may be heavily weighted towards passive investors, with the three individuals providing a significant amount of oversight and control.
The findings of this article provide insight into the ownership structure of Aegis Sciences Corporation and suggest that further research is needed to fully understand the implications of the company’s ownership structure. Such research could focus on how the ownership structure affects the company’s strategic decisions and performance.
(Note: Is this article not meeting your expectations? Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)